Navigation Links
Reportlinker Adds Forecast Insight: Antihypertensives - Fixed-dose combinations fail to offset generic erosion

NEW YORK, Jan. 11, 2011 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Forecast Insight: Antihypertensives - Fixed-dose combinations fail to offset generic erosion

IntroductionAs branded angiotensin receptor blockers (ARBs) lose market exclusivity, fixed-dose combinations become the only remaining products able to generate growth in the antihypertensives market. However, they will not be able to do enough to prevent market erosion which will fall from $37.5 billion in 2009 to $28.6 billion in 2019 at -3% CAGR.

Features and benefits

* Analysis of revenue and volume sales of antihypertensive drug classes in the seven major markets* Assess the impact of key patent expiries, such as Merck & Co's Cozaar and Hyzaar* Forecast antihypertensive revenue and volume sales to 2019, including performance of developmental agents* Understand the impact of clinical trials and pipeline agents on future market dynamics

HighlightsThe first triple drug combination; Exforge HCT (valsartan + amlodipine + hydrochlorothiazide) has reached the US market. Valturna (aliskiren + valsartan; Novartis) has combined the direct renin inhibitor aliskiren with the ARB valsartan to become the first drug to offer dual blockade of the renin angiotensin system.The only innovative antihypertensive agent expected to launch by 2019 is Takeda's ARB; azilsartan medoxomil (TAK-491). Launching in this time frame will make azilsartan an extremely late entry to the ARB class and the drug is going to experience of number of resistors to success.Japan has seen a number of recent launches of ARB combinations. If the new launches replicate the success of Hyzaar (launched in 2006) and Japanese physicians accept the ARB + CCB (calcium channel blocker) combination this will represent the strongest opportunity for class growth in the seven major markets.

Your key questions answered* Quantify and qualify antihypertensive sales in each of the seven major markets for 2006–2019* Examine the future performance of leading antihypertensive brands and how the growth of generics will impact revenues* Understand challenges faced by pipeline agents and new fixed-dose-combinations

To order this report:: Forecast Insight: Antihypertensives - Fixed-dose combinations fail to offset generic erosion

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!Contact:Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds US Disposable Medical Supplies Market Report
2. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
3. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
4. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
5. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
6. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
7. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
8. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
9. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
10. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
11. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
Post Your Comments:
(Date:12/1/2015)... India , December 1, 2015 ... and segments the concerned market with analysis and forecast ... orthobiologics report defines and segments the concerned market ... According to the Market Research Report "North American Orthobiologics ... Growth Factors & Spinal Stimulation, Stem Cell Therapy, Viscosupplementation), ...
(Date:12/1/2015)... and UPPSALA, Sweden , December 1, 2015 ... by the International Breast Cancer Study Group (IBCSG, ... Brussels ) to be part of a state ... promising new cancer drug.  --> ... advanced breast cancer being treated with anti-hormonal therapy in combination ...
(Date:12/1/2015)... , December 1, 2015 ... the addition of the  "2016 Shigella ... Innovative Technologies, Competitive Strategies, Emerging Opportunities--US, ... Japan"  report to their offering. ... the addition of the  "2016 Shigella ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... SAN FRANCISCO, Calif. ... that the organization has awarded Education and Developmental Therapies (EDT), an Applied Behavior ... award celebrates exceptional special needs providers that excel in synthesizing the areas of ...
(Date:12/1/2015)... ... 01, 2015 , ... Lutronic, a leading innovator of aesthetic and medical laser ... devices for sale in the United States. Clarity is a Superior Dual Wavelength ... lasers, into a single platform that is easy to own and operate. , ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... XTC ... selected 10 semi-finalists to head to Las Vegas for CES 2016, the world’s largest ... CEO of Consumer Technology Association Gary Shapiro, Founding Partner of Pacific Investments Veronica Serra, ...
(Date:12/1/2015)... ... ... Nurotron Biotechnology Co., Ltd., maker of cochlear implant systems, has won a ... will be from the China Disabled Persons’ Federation, a central government association, for nearly ... children and adults suffering from severe and profound hearing loss . The company ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... Center Enterprise Authorized Technology Provider (ATP) status from Cisco. This designation recognizes Tympani ... support Cisco Unified Contact Center solutions targeted to the high-end enterprise contact center ...
Breaking Medicine News(10 mins):